NCT00291473View on ClinicalTrials.gov

Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2008

Study Completion Date

August 31, 2008

Conditions
Esophageal CancerLung CancerStomach CancerBreast CancerOvarian Cancer
Interventions
DRUG

CHP-HER2, CHP-NY-ESO-1

Trial Locations (1)

514-8507

Mie University Hospital, Tsu

Sponsors
All Listed Sponsors
collaborator

Mie University

OTHER

lead

Ludwig Institute for Cancer Research

OTHER